Author : Lyalkin S.A.
Functional status of the thyroid gland as a factor modifying the level of PD-L1 expression by tumor cells and immunocompetent T cells of the paratumoral microenvironmentAuthors: Kolomiiets А.А. Lyalkin S.A. Дата: 2026-06-04
Lonsurf® as a cardio-gentle alternative to classical fluoropyrimidinesAuthor:Lyalkin S.A. Т. 16, №1 (61)
Therapeutic options for breast cancer with low HER2/NEU expressionAuthors: Chovgan O.E. Samuseva A.A. Lyalkin S.A. Т. 15, №4 (60)
NALIRIFOX protocol as a new standard of care for metastatic pancreatic cancerAuthor:Lyalkin S.A. Т. 15, №4 (60)
Experience of management of breast cancer in pregnant patient of 28–29 weeks of gestationAuthors: Dronova V.L. Dronov O.I. Lyalkin S.A. Mokryk О.М.... Т. 14, №4 (56)
Features of immune microenvironment in Her2 low breast cancerAuthors: Lyalkin S.A. Krotevich M.S. Smolanka I.I. Shudrak P.A.... Т. 14, №3 (55)
The course features of HER2/neu-low breast cancerAuthors: Bondar M.V. Syvak L.A. Tarasenko T.Ye. Martynyuk O.M.... Т. 13, № 2 (50)
